Clinical Trial Update: Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial evaluates safety, tolerability, and pharmacokinetics of exidavnemab in patients with Parkinson's disease and multiple system atrophy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple System Atrophy
• Parkinson Disease

Drugs mentioned

• Exidavnemab (exidavnemab)

Snippet

Sponsor: BioArctic AB | Conditions: Parkinson Disease, Multiple System Atrophy | Phase 2 | Status: ACTIVE_NOT_RECRUITING